title: Pulsating electromagnetic field stimulation prevents cell death of puromycin treated U937 cell line.
abstract: Aim of study was to verify whether pulsating electromagnetic field (PEMF) can affect cancer cells proliferation and death. U937 human lymphoid cell line at densities starting from 1 x 10(6) cells/ml to 0.0625 x 10(6) cells/ml, were exposed to a pulsating magnetic field 50 Hz, 45+/-5 mT three times for 3 h per each stimulation with 24 h intervals. Proliferation has been studied by counting number of cells stimulated and non-stimulated by PEMF during four days of cultivation. Viability of cells was analyzed by APC labeled Annexin V and 7-AAD (7-amino-actinomycin D) dye binding and flow cytometry. Growing densities of cells increase cell death in cultures of U937 cells. PEMF exposition decreased amount of cells only in higher densities. Measurement of Annexin V binding and 7-AAD dye incorporation has shown that density-induced cell death corresponds with decrease of proliferation activity. PEMF potentiated density-induced death both apoptosis and necrosis. The strongest influence of PEMF has been found for 1 x 10(6)cells/ml and 0.5 x 10(6) cells/ml density. To eliminate density effect on cell death, for further studies density 0.25 x 10(6) cells/ml was chosen. Puromycin, a telomerase inhibitor, was used as a cell death inducer at concentration 100 microg/ml. Combined interaction of three doses of puromycin and three fold PEMF interaction resulted in a reduced of apoptosis by 24,7% and necrosis by 13%. PEMF protects U937 cells against puromycin- induced cell death. PEMF effects on the human lymphoid cell line depends upon cell density. Increased density induced cells death and on the other hand prevented cells death induced by puromycin.
authors.affiliation: Department of Pathophysiology, Jagiellonian University Medical College, Cracow, Poland. jkaszuba@cm-uj.krakow.pl
authors.forename: J
authors.initials: J
authors.lastname: Kaszuba-Zwoinska
authors.forename: K
authors.initials: K
authors.lastname: Wojcik
authors.forename: M
authors.initials: M
authors.lastname: Bereta
authors.forename: A
authors.initials: A
authors.lastname: Ziomber
authors.forename: P
authors.initials: P
authors.lastname: Pierzchalski
authors.forename: E
authors.initials: E
authors.lastname: Rokita
authors.forename: J
authors.initials: J
authors.lastname: Marcinkiewicz
authors.forename: W
authors.initials: W
authors.lastname: Zaraska
authors.forename: P
authors.initials: P
authors.lastname: Thor
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004574:Electromagnetic Fields; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000473:pathology*; D009336:Necrosis / Q000473:pathology; D011691:Puromycin / Q000008:administration & dosage / Q000494:pharmacology*; D020298:U937 Cells
chemical_list: D000964:Antimetabolites, Antineoplastic; D011691:Puromycin